PLANTATION, Fla., Oct. 28 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to present at BIO-
Europe 2004, on Wednesday, November 10 in Cologne, Germany. Hosted by the
Biotechnology Industry Organization, it is Europe's largest event dedicated to
bringing together international decisionmakers in the biotechnology,
pharmaceutical and financial sectors to initiate or develop partnerships.
Event: Viragen Presentation at BIO-Europe 2004
When: Wednesday, November 10 at 12:30 p.m.
Where: Congress-Centrum West, Presentation Room A, Cologne, Germany
To Register: Please visit http://www.bio.org
To Schedule an Appointment with Viragen at the Event:
Contact Douglas Calder at 954-233-8746 or at dcalder@viragen.com
Viragen's Product & Technology Portfolio:
* Multiferon(R) is a highly purified, multi-subtype, natural human alpha
interferon derived from human white blood cells. It is approved for sale in
eight countries, including Sweden, and it is primarily marketed for the
treatment of hepatitis C, malignant melanoma and other cancers. Viragen
recently announced statistically significant results from a 7-year follow-up
to a German Phase II/III cancer clinical study that will serve as the basis
for an application Viragen intends to file in Sweden this year to seek
expanded approval for Multiferon(R) to include the first-line adjuvant
treatment of high-risk malignant melanoma.
* VG101 (anti-GD3 Antibody) -- Viragen is collaborating with Memorial-
Sloan Kettering Cancer Center (New York City) to produce a therapeutic
humanized monoclonal antibody for the treatment of malignant melanoma.
* VG102 (anti-CD55 Antibody) -- Designed for the treatment of a broad
range of cancers, Viragen is collaborating with Cancer Research UK and the
University of Nottingham (England) to develop a humanized monoclonal antibody
designed to deactivate the protective effect of the protein CD55 on the
surface of tumor cells.
* VG104 (IEP 11/MUC1 Peptide) -- Viragen is collaborating with the
University of Miami and the UM/Sylvester Comprehensive Cancer Center to
develop a novel peptide drug based on a variant of the mucin-1 antigen that
has shown dramatic promise by inhibiting the growth of a number of tumor types
in "in vivo" models.
* Avian Transgenic Biomanufacturing Technology -- In collaboration with
Roslin Institute (Scotland), Viragen is developing avian transgenics as an
efficient and economical platform for the large-scale production of
therapeutic proteins by utilizing flocks of transgenic chickens capable of
laying eggs that express high volumes of target therapeutic proteins, such as
a monoclonal antibodies, in the egg whites.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made. Guests scheduled to present at this event are
potentially subject to be replaced, rescheduled or canceled due to unforeseen
conflicts.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
http:www.bio.org
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, +1-954-233-8746, or fax +1-954-233-1414, or
dcalder@viragen.com
|
